These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38404012)

  • 1. Successful switch to cisplatin-based chemotherapy in a patient with lung cancer who developed a carboplatin-induced hypersensitivity reaction.
    Nagata Y; Toyokawa G; Sugiyama A; Shimamatsu S; Saitoh O; Okubo H; Ueda H
    J Oncol Pharm Pract; 2024 Jun; 30(4):772-776. PubMed ID: 38404012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
    Rizvi NA; Hellmann MD; Brahmer JR; Juergens RA; Borghaei H; Gettinger S; Chow LQ; Gerber DE; Laurie SA; Goldman JW; Shepherd FA; Chen AC; Shen Y; Nathan FE; Harbison CT; Antonia S
    J Clin Oncol; 2016 Sep; 34(25):2969-79. PubMed ID: 27354481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non-small-cell Lung Cancer in China.
    Li X; Abbas M; Li Y; Teng Y; Fang Y; Yu S; Wen Y; Wang L; Shi M
    Clin Ther; 2019 Mar; 41(3):518-529. PubMed ID: 30846285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients.
    Tanaka M; Hattori Y; Ishii T; Tohnai R; Itoh S; Kawa Y; Kono Y; Urata Y; Satouchi M
    Respir Investig; 2020 Jul; 58(4):269-274. PubMed ID: 32111518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non-small-cell lung cancer.
    Yamamoto N; Satouchi M; Doi T; Fujiwara Y; Yanagitani N; Kawa Y; Yoh K; Leopold L; Munteanu M; Sawada T; Han S; Noguchi K; Nishio M
    Invest New Drugs; 2024 Jun; 42(3):261-271. PubMed ID: 38530565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin.
    Bergamini A; Pisano C; Di Napoli M; Arenare L; Della Pepa C; Tambaro R; Facchini G; Gargiulo P; Rossetti S; Mangili G; Pignata S; Cecere SC
    Gynecol Oncol; 2017 Jan; 144(1):72-76. PubMed ID: 28094039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
    de Castria TB; da Silva EM; Gois AF; Riera R
    Cochrane Database Syst Rev; 2013 Aug; (8):CD009256. PubMed ID: 23949842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study.
    Gadgeel SM; Stevenson JP; Langer CJ; Gandhi L; Borghaei H; Patnaik A; Villaruz LC; Gubens M; Hauke R; Yang JC; Sequist LV; Bachman R; Saraf S; Raftopoulos H; Papadimitrakopoulou V
    Lung Cancer; 2018 Nov; 125():273-281. PubMed ID: 30429032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.
    Soria JC; Adjei AA; Bahleda R; Besse B; Ferte C; Planchard D; Zhou J; Ware J; Morrissey K; Shankar G; Lin W; Schutzman JL; Dy GK; Groen HJM
    Eur J Cancer; 2017 Nov; 86():186-196. PubMed ID: 28992562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer.
    Eberhardt WE; Mitchell P; Schiller JH; Brown MP; Thomas M; Mills G; Jehl V; Urva SR; De Leo JJ; Gogov S; Papadimitrakopoulou V
    Invest New Drugs; 2014 Feb; 32(1):123-34. PubMed ID: 23579358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
    Langer CJ; Gadgeel SM; Borghaei H; Papadimitrakopoulou VA; Patnaik A; Powell SF; Gentzler RD; Martins RG; Stevenson JP; Jalal SI; Panwalkar A; Yang JC; Gubens M; Sequist LV; Awad MM; Fiore J; Ge Y; Raftopoulos H; Gandhi L;
    Lancet Oncol; 2016 Nov; 17(11):1497-1508. PubMed ID: 27745820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.
    Satouchi M; Nosaki K; Takahashi T; Nakagawa K; Aoe K; Kurata T; Sekine A; Horiike A; Fukuhara T; Sugawara S; Umemura S; Saka H; Okamoto I; Yamamoto N; Sakai H; Kishi K; Katakami N; Horinouchi H; Hida T; Okamoto H; Atagi S; Ohira T; Han SR; Noguchi K; Ebiana V; Hotta K
    Cancer Sci; 2020 Dec; 111(12):4480-4489. PubMed ID: 32926507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
    Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Vandormael K; Riccio A; Yang J; Pietanza MC; Brahmer JR
    J Clin Oncol; 2019 Mar; 37(7):537-546. PubMed ID: 30620668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
    Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622).
    Feliciano JL; Le-Rademacher JG; Gajra A; Edelman MJ; Zemla T; McMurray R; Chen H; Hurria A; Muss H; Cohen HJ; Lilenbaum R; Jatoi A
    J Geriatr Oncol; 2018 Sep; 9(5):501-506. PubMed ID: 29848457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trial.
    Quoix E; Audigier-Valette C; Lavolé A; Molinier O; Westeel V; Barlesi F; Le Treut J; Pichon E; Dauba J; Otto J; Moreau L; Madelaine J; Dumont P; Margery J; Debieuvre D; Renault PA; Pujol JL; Langlais A; Morin F; Moro-Sibilot D; Souquet PJ
    Eur J Cancer; 2020 Oct; 138():193-201. PubMed ID: 32898792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypersensitivity Reaction to Carboplatin in Gynecologic Cancer: A Case Report and a Review of the Literature.
    Aoyama Y; Ueda T; Kuradome Y; Hoshino K; Harada H; Kinjo Y; Murakami M; Kagami S; Yoshino K
    J UOEH; 2021; 43(1):81-86. PubMed ID: 33678789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer.
    Nuijten MJ; Aultman R; Carpeño Jde C; Vergnenègre A; Chouaid C; Walzer S; Siebert U
    Curr Med Res Opin; 2011 Nov; 27(11):2193-201. PubMed ID: 21970659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
    Vasconcellos VF; Marta GN; da Silva EM; Gois AF; de Castria TB; Riera R
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD009256. PubMed ID: 31930743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer.
    Kehl KL; Greenwald S; Chamoun NG; Manberg PJ; Schrag D
    JAMA Netw Open; 2021 May; 4(5):e2111113. PubMed ID: 34019086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.